[Effect of halofenate on triglyceride and uric acid levels, coagulation and platelet behaviour in patients with hyperlipoproteinemia type IV and hyperuricemia (author's transl)].
From experimental work, an influence of a drug with hypolipidemic and hypouricemic acition on blood coagulability and platelet function may be expected. Consequently, if these effects were demonstrable in man the drug could be assumed to reduce the tendency to develop thrombosis and atherosclerosis in patients with hyperlipidemia and hyperuricemia. In the study reported, the effect of 2-acetamidoethyl-(p-chlorophenyl)-(m-trifluoro-methylphenoxy)-acetate (halofenate) was investigated in 14 patients suffering from hyperlipoproteinemia type IV and hyperuricemia. Platelet aggregation and adhesiveness, plasma levels of triglycerides, cholesterol, uric acid, and clotting factors were regularly examined during a three-month double blind trial. While uric acid and triglyceride levels decreased, no influence of the drug treatment could be observed on platelet function and blood coagulability by the laboratory methods used.
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D006016:Glycolates / Q000494:pharmacology*; D006218:Halofenate / Q000494:pharmacology*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D014280:Triglycerides / Q000097:blood*; D014527:Uric Acid / Q000097:blood*
D006016:Glycolates; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol; D006218:Halofenate
Wirkung von Halofenat auf Triglycerid- und Harnsäurespiegel sowie auf Gerinnungs- und Thrombozytenverhalten bei Patienten mit Hyperlipoproteinämie Typ IV und Hyperurikämie.